Bexsero, meningitis B vaccine vaccination campaign results released
Novartis has announced the initial results of a large-scale vaccination campaign with Bexsero® (Meningococcal Group B Vaccine [rDNA, component, adsorbed]) to help protect against meningitis B within the Saguenay-Lac-Saint-Jean More...
Novartis seeks FDA approval for meningitis B vaccine, Bexsero
Basel, June 17, 2014 – Novartis announced today the submission of a Biologic License Application (BLA) to the US Food and Drug Administration (FDA) for marketing approval for the use of Bexsero® (Multicomponent More...
Bexsero, meningitis B vaccine, receives FDA Breakthrough Therapy designation
PRESS RELEASE Novartis announced today that Bexsero® (Meningococcal Group B Vaccine [rDNA, component, adsorbed]) has received a Breakthrough Therapy designation from the United States Food and Drug Administration More...
What is Bexsero? How common is meningococcal disease serogroup B?
With the eighth case of meningococcal meningitis confirmed at Princeton University yesterday, and at least seven confirmed as Neisseria meningitis serotype B (MenB) with the most recent still pending, health officials More...
Bexsero, first Meningitis B vaccine, receives European Commission approval
Photo/CDC/ Debora Cartagena Switzerland-based pharmaceutical and health care company, Novartis announced this week that it’s Meningitis B vaccine, Bexsero, has received approval from the European Commission More...
